PENN Neuroendocrine Tumor Cme Symposium: A CME-Certified Course

The Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 26 de julio del 2011

Share article


Friday, September 9, 2011

7:30 AM — 8:00 AM Registration and Continental Breakfast
8:00 AM — 5:00 PM Educational Session

Download Conference PDF

University of Pennsylvania Biomedical Research Building II/III
421 Curie Boulevard
Philadelphia, PA

Course Directors:
Debbie L. Cohen, MD
David C. Metz, MD

This conference is designed for endocrinologists, internists, oncologists, gastroenterologists, geneticists, nephrologists, pathologists, radiologists, specialists in nuclear medicine, physician assistants, nurses, nurse practitioners and other allied health professionals.

Neuroendocrine tumors (NETs) consist of a relatively homogeneous group of tumors that are often well-differentiated and associated with an indolent clinical course. While considered to be rare, their incidence has been on the rise
(the prevalence of these tumors is quite large, >100,000 in the USA). These tumors develop from the neuroendocrine cells dispersed throughout the body and they are generally incurable in the setting of metastatic disease. Due to their ability to produce hormones, their clinical presentations can be rather dramatic and varied. Successful management requires an understanding of the disease process as a whole and a multi-modality approach with contributions from medical oncology, surgery, endocrinology, gastroenterology,
nephrology, pathology, interventional and diagnostic radiology, nuclear medicine and genetics.

This CME program has been designed to provide cutting edge information on all aspects of NET patient management.

Course Objectives

Upon completion of the program, learners should be able to:

  • Identify the appropriate tests to diagnose pheochromocytoma and conduct the appropriate work-up
  • Describe the genetic mutations associated with pheochromocytomas, paragangliomas and other neuroendocrine tumors and how these mutations affect prognosis and treatment options
  • Diagnose, stage and treat patients with alimentary tract neuroendocrine tumors
  • Review the interdisciplinary components of state-of-the-art management of patients with neuroendocrine tumors

For more information, please see the conference PDF.


News
Chemo Combo Promising for Pancreatic Neuroendocrine Tumors

Jul 17, 2012 - The combination of temozolomide and bevacizumab seems to benefit patients with advanced pancreatic neuroendocrine tumors, according to a study published online July 9 in the Journal of Clinical Oncology.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Frente a un nuevo diagnóstico de cáncer o de cambiar el curso de su tratamiento actual? Deje que nuestro personal de enfermería cáncer que ayudan a pasar!

Más información